[1]

Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics-2019 update: a report from the American Heart Association. Circulation 2019; 139: e56−e528.

[2] Lassen JF, Botker HE, Terkelsen CJ. Timely and optimal treatment of patients with STEMI. Nat Rev Cardiol 2013; 10: 41−48. doi: 10.1038/nrcardio.2012.156 [3] Hausenloy DJ, Yellon DM. Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J Clin Invest 2013; 123: 92−100. doi: 10.1172/JCI62874 [4] Hotchkiss RS, Strasser A, McDunn JE, Swanson PE. Cell death. N Engl J Med 2009; 361: 1570−1583. doi: 10.1056/NEJMra0901217 [5] Chang X, Toan S, Li R, Zhou H. Therapeutic strategies in ischemic cardiomyopathy: Focus on mitochondrial quality surveillance. EBioMedicine 2022; 84: 104260. doi: 10.1016/j.ebiom.2022.104260 [6] Zhou H, Ren J, Toan S, Mui D. Role of mitochondrial quality surveillance in myocardial infarction: From bench to bedside. Ageing Res Rev 2021; 66: 101250. doi: 10.1016/j.arr.2020.101250 [7]

Harrell CR, Jovicic N, Djonov V, et al. Mesenchymal stem cell-derived exosomes and other extracellular vesicles as new remedies in the therapy of inflammatory diseases. Cells 2019; 8.

[8] Bagno L, Hatzistergos KE, Balkan W, Hare JM. Mesenchymal stem cell-based therapy for cardiovascular disease: progress and challenges. Mol Ther 2018; 26: 1610−1623. doi: 10.1016/j.ymthe.2018.05.009 [9] Meng SS, Guo FM, Zhang XW, et al. mTOR/STAT-3 pathway mediates mesenchymal stem cell-secreted hepatocyte growth factor protective effects against lipopolysaccharide-induced vascular endothelial barrier dysfunction and apoptosis. J Cell Biochem 2019; 120: 3637−3650. doi: 10.1002/jcb.27642 [10] Bianchi ME, Agresti A. HMG proteins: dynamic players in gene regulation and differentiation. Curr Opin Genet Dev 2005; 15: 496−506. doi: 10.1016/j.gde.2005.08.007 [11] Harris HE, Raucci A. Alarmin(g) news about danger: workshop on innate danger signals and HMGB1. EMBO Rep 2006; 7: 774−778. doi: 10.1038/sj.embor.7400759 [12] Bianchi ME, Manfredi AA. High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol Rev 2007; 220: 35−46. doi: 10.1111/j.1600-065X.2007.00574.x [13] Huang H, Nace GW, McDonald KA, et al. Hepatocyte-specific high-mobility group box 1 deletion worsens the injury in liver ischemia/reperfusion: a role for intracellular high-mobility group box 1 in cellular protection. Hepatology 2014; 59: 1984−1997. doi: 10.1002/hep.26976 [14] [15] Bromberg J, Wang TC. Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell 2009; 15: 79−80. doi: 10.1016/j.ccr.2009.01.009 [16] Poynter JA, Herrmann JL, Manukyan MC, et al. Intracoronary mesenchymal stem cells promote postischemic myocardial functional recovery, decrease inflammation, and reduce apoptosis via a signal transducer and activator of transcription 3 mechanism. J Am Coll Surg 2011; 213: 253−260. doi: 10.1016/j.jamcollsurg.2011.04.005 [17] Chu X, Xu B, Gao H, et al. Lipopolysaccharides improve mesenchymal stem cell-mediated cardioprotection by MyD88 and STAT3 signaling in a mouse model of cardiac ischemia/reperfusion injury. Stem Cells Dev 2019; 28: 620−631. doi: 10.1089/scd.2018.0213 [18]

Boucher F. Ng, S, Koh S, et al. PDGF, TGF-beta, and FGF signaling is important for differentiation and growth of mesenchymal stem cells (MSCs): transcriptional profiling can identify markers and signaling pathways important in differentiation of MSCs into adipogenic, chondrogenic, and osteogenic lineages. Blood 2008; 112: 295–307.

[19]

Nakahara M. [Malignant rheumatoid arthritis]. Hokkai Igaku Zasshi 1975; 50: 278–280. [In Japanese].

[20]

Kulik AM, Kondrat'eva LN. [Combined effects of hypoxia and hypercapnia on the functional state of the respiratory center]. Biull Eksp Biol Med 1975; 79: 39–43. [In Russian].

[21]

Isaac O, Thiemer K. [Biochemical studies on camomile components/III. In vitro studies about the antipeptic activity of (--)-alpha-bisabolol (author's transl)]. Arzneimittelforschung 1975; 25: 1352–1354. [In German].

[22] Mastri M, Lin H, Lee T. Enhancing the efficacy of mesenchymal stem cell therapy. World J Stem Cells 2014; 6: 82−93. doi: 10.4252/wjsc.v6.i2.82 [23] Lee SC, Jeong HJ, Lee SK, Kim SJ. Lipopolysaccharide preconditioning of adipose-derived stem cells improves liver-regenerating activity of the secretome. Stem Cell Res Ther 2015; 6: 75. doi: 10.1186/s13287-015-0072-7 [24]

Chang X, Lochner A, Wang HH, et al. Coronary microvascular injury in myocardial infarction: perception and knowledge for mitochondrial quality control. Theranostics 2021. 11: 6766–6785.

[25] Liu J, Kam KW, Zhou JJ, et al. Effects of heat shock protein 70 activation by metabolic inhibition preconditioning or kappa-opioid receptor stimulation on Ca2+ homeostasis in rat ventricular myocytes subjected to ischemic insults. J Pharmacol Exp Ther 2004; 310: 606−613. doi: 10.1124/jpet.104.067926 [26]

Kamiya T, Kwon AH, Kanemaki T, et al. A simplified model of hypoxic injury in primary cultured rat hepatocytes. In Vitro Cell Dev Biol Anim 1998; 34: 131−137.

[27] Li T, Tian H, Li J, et al. Overexpression of lncRNA Gm2691 attenuates apoptosis and inflammatory response after myocardial infarction through PI3K/Akt signaling pathway. IUBMB Life 2019; 71: 1561−1570. doi: 10.1002/iub.2081 [28] Masaki M, Izumi M, Oshima Y, et al. Smad1 protects cardiomyocytes from ischemia-reperfusion injury. Circulation 2005; 111: 2752−2759. doi: 10.1161/CIRCULATIONAHA.104.490946 [29] Delewi R, Andriessen A, Tijssen JG, et al. Impact of intracoronary cell therapy on left ventricular function in the setting of acute myocardial infarction: a meta-analysis of randomised controlled clinical trials. Heart 2013; 99: 225−232. doi: 10.1136/heartjnl-2012-302230 [30] Hare JM, Fishman JE, Gerstenblith G, et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA 2012; 308: 2369−2379. doi: 10.1001/jama.2012.25321 [31] Gnecchi M, He H, Noiseux N, et al. Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J 2006; 20: 661−669. doi: 10.1096/fj.05-5211com [32]

Shafei AE, Ali MA, Ghanem HG, et al. Mesenchymal stem cell therapy: A promising cell-based therapy for treatment of myocardial infarction. J Gene Med 2017; 19.

[33] Javaherian K, Liu JF, Wang JC. Nonhistone proteins HMG1 and HMG2 change the DNA helical structure. Science 1978; 199: 1345−1346. doi: 10.1126/science.628842 [34] Tirone M, Tran NL, Ceriotti C, et al. High mobility group box 1 orchestrates tissue regeneration via CXCR4. J Exp Med 2018; 215: 303−318. doi: 10.1084/jem.20160217 [35] Raucci A, Di Maggio S, Scavello F, et al. The Janus face of HMGB1 in heart disease: a necessary update. Cell Mol Life Sci 2019; 76: 211−229. doi: 10.1007/s00018-018-2930-9 [36] Lin F, Xue D, Xie T, Pan Z. HMGB1 promotes cellular chemokine synthesis and potentiates mesenchymal stromal cell migration via Rap1 activation. Mol Med Rep 2016; 14: 1283−1289. doi: 10.3892/mmr.2016.5398 [37] Tao X, Sun M, Chen M, et al. HMGB1-modified mesenchymal stem cells attenuate radiation-induced vascular injury possibly via their high motility and facilitation of endothelial differentiation. Stem Cell Res Ther 2019; 10: 92. doi: 10.1186/s13287-019-1197-x [38] Bianchi ME, Crippa MP, Manfredi AA, et al. High-mobility group box 1 protein orchestrates responses to tissue damage via inflammation, innate and adaptive immunity, and tissue repair. Immunol Rev 2017; 280: 74−82. doi: 10.1111/imr.12601 [39] Yang C, Lee H, Pal S, et al. B cells promote tumor progression via STAT3 regulated-angiogenesis. PLoS One 2013; 8: e64159. doi: 10.1371/journal.pone.0064159 [40] Yun S, Yun CW, Lee JH, et al. Cripto enhances proliferation and survival of mesenchymal stem cells by up-regulating JAK2/STAT3 pathway in a GRP78-dependent manner. Biomol Ther (Seoul) 2018; 26: 464−473. doi: 10.4062/biomolther.2017.099